OCUL

8.49

1.92% 0.16

Dopo l'orario di chiusura: 8.55 0.06 +0.71%

Ocular Therapeutix Inc (OCUL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché OCUL Giù? Forum Previsione

Precedente Chiudi:

$8.33

Aprire:

$8.09

Volume 24 ore:

4.37M

Relative Volume:

0.73

Capitalizzazione di mercato:

$1.85B

Reddito:

$51.95M

Utile/perdita netta:

$-265.94M

Rapporto P/E:

-5.9024

EPS:

-1.4384

Flusso di cassa netto:

$-216.89M

1 W Prestazione:

+5.20%

1M Prestazione:

-22.68%

6M Prestazione:

-23.24%

1 anno Prestazione:

+15.67%

Intervallo 1D:

$8.09

$8.73

Intervallo di 1 settimana:

$7.38

$8.75

Portata 52W:

$5.80

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Nome

Ocular Therapeutix Inc

Settore

Healthcare (1118)

Industria

Biotechnology (624)

Telefono

781-357-4000

Indirizzo

15 CROSBY DRIVE, BEDFORD, MA

Dipendente

325

Cinguettio

@OCUTX

Prossima data di guadagno

2025-03-03

Ultimi documenti SEC

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OCUL Ocular Therapeutix Inc	8.49	1.85B	51.95M	-265.94M	-216.89M	-1.4384
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-09-15	Iniziato	Chardan Capital Markets	Buy
2025-04-08	Iniziato	William Blair	Outperform
2025-03-18	Iniziato	RBC Capital Mkts	Outperform
2025-03-11	Iniziato	Needham	Buy
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-06-20	Aggiornamento	TD Cowen	Hold → Buy
2024-05-31	Ripresa	Piper Sandler	Overweight
2024-02-09	Iniziato	BofA Securities	Buy
2023-04-21	Iniziato	Robert W. Baird	Outperform
2022-08-10	Ripresa	Berenberg	Buy
2021-08-10	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-28	Downgrade	H.C. Wainwright	Buy → Neutral
2020-12-17	Iniziato	Berenberg	Buy
2020-11-13	Reiterato	Raymond James	Strong Buy
2020-08-10	Reiterato	H.C. Wainwright	Buy
2020-03-03	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-05-21	Downgrade	Cowen	Outperform → Market Perform
2019-05-21	Reiterato	H.C. Wainwright	Buy
2019-05-21	Downgrade	Raymond James	Strong Buy → Outperform
2018-12-03	Reiterato	Cantor Fitzgerald	Overweight
2018-11-15	Iniziato	Raymond James	Strong Buy
2018-09-07	Iniziato	Piper Jaffray	Overweight
2017-10-24	Iniziato	Guggenheim	Buy
2017-07-26	Iniziato	H.C. Wainwright	Buy
2017-07-12	Reiterato	Cantor Fitzgerald	Overweight
2017-06-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Iniziato	Cantor Fitzgerald	Overweight
2016-11-15	Reiterato	RBC Capital Mkts	Outperform
2016-08-11	Iniziato	JMP Securities	Mkt Outperform
2016-02-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie

08:14 AM

HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN

Apr 02, 2026

OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill

Apr 02, 2026

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Sahm

Apr 02, 2026

Apr 01, 2026

Analysis Recap: How sensitive is Ocular Therapeutix Inc to inflation2026 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Apr 01, 2026

OCUL Earning Date, Earning Analysis and Earning Prediction - intellectia.ai

Apr 01, 2026

Ocular lines up April talks on wet AMD trial data and retinal disease - Stock Titan

Apr 01, 2026

Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds - Insider Monkey

Apr 01, 2026

Mar 31, 2026

Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - Moomoo

Mar 31, 2026

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3%Should You Buy? - MarketBeat

Mar 31, 2026

Mar 30, 2026

OCULAR THERAPEUTIX (01477.HK) Completes First Patient Enrollment in Phase III Clinical Trial for OT-211 - AASTOCKS.com

Mar 30, 2026

Mar 29, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 34.2% in March - MarketBeat

Mar 29, 2026

Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat

Mar 29, 2026

Mar 28, 2026

Why Ocular Therapeutix (OCUL) Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim - Sahm

Mar 28, 2026

Mar 27, 2026

What Ocular Therapeutix (OCUL)'s Single-Study FDA Bid After SOL-1 Superiority Means For Shareholders - Yahoo Finance

Mar 27, 2026

Vanguard reports zero holdings in Ocular Therapeutix (OCUL) - Stock Titan

Mar 27, 2026

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com

Mar 27, 2026

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com UK

Mar 27, 2026

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21 - Moomoo

Mar 27, 2026

Mar 26, 2026